Copeptin as a Biomarker of Atherosclerosis in Type 1 Diabetic Patients

Abstract

AIM: To evaluate copeptin as an early marker of atherosclerosis in adolescent type 1 diabetics.
 METHODS: Sixty-two type 1 diabetic patients and 50 healthy volunteers were enrolled in the study. Serum copeptin, glycosylated haemoglobin (HbA1c), lipid profile, oxidised low-density lipoprotein (OxLDL), urinary albumin/creatinine ratio, carotid intimal medial thickness (cIMT), aortic intimal medial thickness (aIMT) and resistivity index were assessed for all participant in the study.
 RESULTS: HbA1, albumin/creatinine ratio, lipid profile, OxlDL, copeptin, cIMT and aIMT were significantly higher in diabetic patients. Copeptin was higher in patients with positive cIMT and aIMT. Copeptin correlated with cIMT and aIMT. Stepwise multiple regression analysis found that copeptin correlated with aIMT. ROC curve showed that copeptin had 100 % specificity with aIMT and cIMT and 95.2 and 60,7 sensitivity with aIMT and cIMT respectively.
 CONCLUSION: Copeptin can be used as a marker for early detection of atherosclerosis of type 1 diabetic patients.

Copeptin: a potential blood biomarker for acute ischemic stroke

“…Our finding is in agreement with Wang and colleagues [21] who found no significant difference in copeptin levels between subjects with normal carotid artery duplex and those who had higher carotid artery intima-media thickness. Unlike El Dayem and colleagues [28], who concluded that copeptin is an inflammatory marker and associated with increase in carotid artery intima-media thickness and can be a predictor for atherosclerosis. The difference between our findings and that of El Dayem and colleagues can be explained by the difference in patient groups, as all the patients included in El Dayem and colleagues study were diabetics, while only 35.6% of our patients were diabetic, many studies elaborated higher copeptin levels in diabetic patients as discussed before.…”

Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease

“…Copeptin is a peptide which derives from the same precursor of arginine vasopressin and is considered a useful biomarker of several pathologic conditions such as myocardial infarction, atherosclerosis and ischemic stroke [ 66 ]. Recent observational studies have discovered that higher blood levels of copeptin are strictly associated with the development of atherosclerosis, arterial stiffness and kidney damage in patients with type 1 diabetes [ 67 , 68 ]. In particular, patients with the highest levels of copeptin have concomitantly increased levels of albuminuria, the main marker of kidney damage [ 69 ].…”